Literature DB >> 32826525

High-grade Neuroendocrine Carcinomas of the Vulva: A Clinicopathologic Study of 16 Cases.

Peter P Chen1, Preetha Ramalingam1, Isabel Alvarado-Cabrero2, Elizabeth D Euscher1, Priyadharsini Nagarajan1, Barrett C Lawson1, Anais Malpica1.   

Abstract

Vulvar high-grade neuroendocrine carcinomas (HGNECs) are rare and primarily thought to represent Merkel cell carcinoma (MCC). We present the clinicopathologic features of 16 such cases, the largest series to date. Patients were most often White, postmenopausal, and symptomatic from a palpable vulvar mass/nodule. Tumors ranged from 0.7 to 6 cm and most commonly involved the labium majus. Majority of the cases were pure HGNECs (15/16) with small cell (SC) morphology (14/16); 2 were large cell neuroendocrine carcinomas, of which 1 was combined with moderately differentiated adenocarcinoma. All tumors expressed synaptophysin. Of the 14 HGNECs with SC morphology, 6 were CK20-positive MCCs with characteristic CAM5.2 and neurofilament (NF) expression. Five of these MCCs were positive for Merkel cell polyoma virus large T-antigen (MCPyVLTAg). In contrast, 6 HGNECs with SC morphology were negative for CK20, NF, and MCPyVLTAg and classified as SCNECs. High-risk human papilloma virus was positive in all SCNECs and negative in all MCCs. One case of HGNEC with SC morphology could not be entirely characterized due to lack of tissue for ancillary testing. Five of 12 (42%) cases had a discrepant diagnosis initially rendered. Most patients (10/15) presented with International Federation of Gynecology and Obstetrics stage III or IV disease. Usual sites of metastasis included inguinal lymph node, liver, bone, and lung. Twelve patients underwent surgery with adjuvant chemotherapy and/or radiation therapy, 1 received adjuvant immunotherapy, and 1 patient received neoadjuvant chemotherapy followed by surgery and adjuvant radiation therapy. Median overall survival was 24 months (range: 7 to 103 mo), and overall 5-year survival was 12% (95% confidence interval: 1% to 39%). In summary, vulvar HGNECs are rare, aggressive neoplasms that can be further subclassified into MCC, SCNEC, and large cell neuroendocrine carcinoma. CK20, CAM5.2, NF, TTF-1, MCPyVLTAg, and high-risk human papilloma virus facilitate the distinction of MCC from SCNEC. Proper identification of vulvar HGNECs is critical for patient management.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 32826525     DOI: 10.1097/PAS.0000000000001558

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

1.  Sweat-gland carcinoma with neuroendocrine differentiation (SCAND): a clinicopathologic study of 13 cases with genetic analysis.

Authors:  Keisuke Goto; Yoji Kukita; Keiichiro Honma; Nobuyuki Ohike; Takaya Komori; Yoshihiro Ishida; Misawo Ishikawa; Takashi Nakatsuka; Soichi Fumita; Koichi Nakagawa; Aya Okabayashi; Yoshifumi Iwahashi; Tomoyuki Tanino; Keisuke Kikuchi; Yoshie Kawahara; Tsunekazu Hishima; Jiro Uehara; Takuma Oishi; Taiki Isei
Journal:  Mod Pathol       Date:  2021-09-12       Impact factor: 7.842

2.  Vulvar neuroendocrine carcinoma that is independent of merkel cell polyomavirus and human papillomavirus suggests endometrial cancer recurrence: a case report.

Authors:  Tomoko Hirakawa; Mitsutake Yano; Haruto Nishida; Shimpei Sato; Kaei Nasu
Journal:  BMC Endocr Disord       Date:  2022-03-29       Impact factor: 2.763

Review 3.  Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract.

Authors:  Tiberiu-Augustin Georgescu; Roxana Elena Bohiltea; Octavian Munteanu; Florentina Furtunescu; Antonia-Carmen Lisievici; Corina Grigoriu; Florentina Gherghiceanu; Emilia Maria Vlădăreanu; Costin Berceanu; Ionita Ducu; Ana-Maria Iordache
Journal:  Medicina (Kaunas)       Date:  2021-12-07       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.